Changes to this Summary (12/03/2013)
The PDQ cancer information summaries are reviewed regularly and updated as new information becomes available. This section describes the latest changes made to this summary as of the date above.
Added text to state that within the hyperdiploid range of 51 to 66 chromosomes, patients with higher modal numbers (58–66) appeared to have a better prognosis in one study.
Added Feng et al. as reference 167.
Added text to state that point mutations within kinase genes are uncommon among Philadelphia chromosome–like (Ph-like) cases, except for JAK1 and JAK2 (cited Loh et al. as reference 171).
Added text to state that point mutations in kinase genes, aside from those in JAK1 and JAK2, are uncommon in Ph-like ALL cases.
Added Burke et al. as reference 27.
Added text to state that with a median follow-up of 65 months, the 5-year event-free survival was 81% for patients who received imatinib compared with 30% for a historic control group treated similarly, but without imatinib; of note, only one of the 16 patients received prophylactic imatinib posttransplant (cited Rives et al. as reference 59).
Added text to state that the results of a phase I trial of dasatinib in pediatric patients indicated that once-daily dosing was associated with an acceptable toxicity profile, with few nonhematologic grade 3 or 4 adverse events (cited Zwaan et al. as reference 62).
Added Bakr et al. as reference 62.
This summary is written and maintained by the PDQ Pediatric Treatment Editorial Board, which is editorially independent of NCI. The summary reflects an independent review of the literature and does not represent a policy statement of NCI or NIH. More information about summary policies and the role of the PDQ Editorial Boards in maintaining the PDQ summaries can be found on the About This PDQ Summary and PDQ NCI's Comprehensive Cancer Database pages.